Skip to content
The Kids Research Institute Australia logo
Donate

Search

PCV10 elicits Protein D IgG responses in Papua New Guinean children but has no impact on NTHi carriage in the first two years of life

Nasopharyngeal colonisation with nontypeable Haemophilus influenzae (NTHi) is associated with development of infections including pneumonia and otitis media. The 10-valent pneumococcal conjugate vaccine (PCV10) uses NTHi Protein D (PD) as a carrier. Papua New Guinean children have exceptionally early and dense NTHi carriage, and high rates of NTHi-associated disease.

Influenza disease and vaccination in children in Australia

Over the past decade, multiple initiatives have been implemented to strengthen influenza vaccination programs in Australia, with an increasing focus on children. In this article, we review these changes, the events that prompted them, and how they have influenced influenza vaccine uptake in Australia.

Inferring temporal trends of multiple pathogens, variants, subtypes or serotypes from routine surveillance data

Estimating the temporal trends in infectious disease activity is crucial for monitoring disease spread and the impact of interventions. Surveillance indicators routinely collected to monitor these trends are often a composite of multiple pathogens. For example, "influenza-like illness"-routinely monitored as a proxy for influenza infections-is a symptom definition that could be caused by a wide range of pathogens, including multiple subtypes of influenza, SARS-CoV-2, and RSV.

Boosting the influenza vaccine schedule in children with cancer: a prospective open-label study

Current immunization guidelines recommend one dose of influenza vaccine for children aged ≥9 years and two doses for younger or vaccine-naïve children. However, children receiving chemotherapy have an attenuated immune response. We performed a prospective open-label study in children undergoing treatment for cancer at Perth Children's Hospital, Western Australia, to examine the safety and efficacy of a boosted influenza schedule.

Latest news & events

Latest news & events at the Wesfarmers Centre of Vaccines & Infectious Diseases.

Warm Welcome for the Neonatal Infection and Immunity Team

Clinical Professor Tobias Strunk, Dr Andrew Currie and their Neonatal Infection and Immunity Team have become the newest members of the Wesfarmers Centre of Vaccines and Infectious Diseases.

Reactogenicity of two 2010 trivalent inactivated influenza vaccine formulations in adults

The objective of this tudy was to assess the reactogenicity of two 2010 trivalent inactivated influenza vaccine (TIV) formulations among adults, including...

Pandemic influenza H1N1 2009 infection in Victoria, Australia

Conflicting findings regarding the level of protection offered by seasonal influenza vaccination against pandemic influenza H1N1 have been reported.

Immunogenicity and safety of a combined Haemophilus influenzae type b-Neisseria

Neisseria meningitidis serogroups B, C, and Y cause most meningococcal disease in industrialized countries...

Influenza vaccine effectiveness against laboratory-confirmed influenza in healthy children aged 6-59 months:

The Western Australian Influenza Vaccine Effectiveness study commenced in 2008 to evaluate a new program to provide free influenza vaccine to all children...